Comparative physiologic effects of telazol, medetomidine-ketamine, and medetomidine-telazol in captive polar bears (Ursus maritimus).
The cardiopulmonary effects of three drug combinations in polar bears (Ursus maritimus) were studied. In 1995, five adult polar bears received i.m. injections of either 8.2 +/- 1.3 mg/kg of Telazol or a combination of 159 +/- 34 microg/kg of medetomidine with 4 +/- 0.8 mg/kg of ketamine in a crossover design. Significantly higher mean arterial pressure, lower heart rate, and lower partial pressure of arterial oxygen (Pao2) occurred with medetomidine-ketamine. In 1996, six adult polar bears were immobilized with i.m. injections of either 8.2 +/- 2 mg/kg of zolazepam-tiletamine or a combination of 74.8 +/- 11.8 microg/kg of medetomidine plus 2.2 +/- 0.3 mg/kg of zolazepam-tiletamine in a crossover design. Significantly higher mean arterial pressure and lower heart rate, base excess, and Pao2 occurred with medetomidine-zolazepam-tiletamine compared with zolazepam-tiletamine alone. Hypertension, bradycardia, and decreased Pao2 were observed with both medetomidine-ketamine and medetomidine-zolazepam-tiletamine. Both combinations should be well tolerated by healthy bears, but both have the potential to produce adverse effects in animals with cardiopulmonary disease. Zolazepam-tiletamine produced minimal adverse cardiopulmonary effects, consistent with the wide margin of safety of this combination in bears. The analgesic effect of zolazepam-tiletamine was apparently poor on the basis of the marked increases in pulse rate and mean arterial pressure after noxious stimuli.
Caulkett
N A
NA
Department of Veterinary Anesthesiology, Radiology, and Surgery, Veterinary Teaching Hospital, Western College of Veterinary Medicine, Saskatchewan, Canada.
Cattet
M R
MR
Caulkett
J M
JM
Polischuk
S C
SC
D019162:Anesthetics, Combined; D000778:Anesthetics, Dissociative; D000818:Animals; D000836:Animals, Zoo; D001146:Arrhythmia, Sinus / Q000139:chemically induced / Q000662:veterinary; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004338:Drug Combinations; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006993:Hypnotics and Sedatives; D007103:Immobilization; D007273:Injections, Intramuscular / Q000662:veterinary; D007649:Ketamine; D008297:Male; D020926:Medetomidine; D010100:Oxygen / Q000097:blood; D012119:Respiration / Q000187:drug effects; D013992:Tiletamine; D001503:Ursidae / Q000502:physiology*; D015041:Zolazepam
D019162:Anesthetics, Combined; D000778:Anesthetics, Dissociative; D004338:Drug Combinations; D006993:Hypnotics and Sedatives; C006131:tiletamine, zolazepam drug combination; D013992:Tiletamine; D007649:Ketamine; D015041:Zolazepam; D020926:Medetomidine; D010100:Oxygen